With a background in molecular biology and clinical chemistry, Henrik Zetterberg, MD, PhD, has spent the last 10 years focusing on the development of biomarkers for Alzheimer’s disease, Parkinson’s disease and other brain disorders. He has developed new diagnostic tests for Alzheimer’s disease, as well as new preclinical models, and has shown that (i) amyloid pathology precedes tau pathology by around five years during the Alzheimer’s disease process in humans, (ii) altered amyloid homeostasis in the brain is evident already in pre-symptomatic stages of the disease, and (iii) the diagnostic usefulness of Alzheimer’s biomarkers decreases with age due to increased prevalence of preclinical Alzheimer neuropathology.

Dr. Zetterberg has received numerous prizes, including the Erik K. Fernström Prize for Junior Scientists and the Inga Sandeborg Prize for Research on Alzheimer’s Disease. He is professor of neurochemistry and head of the Department of Psychiatry and Neurochemistry at the Sahlgrenska Academy, senior consultant in clinical chemistry at the Sahlgrenska University Hospital, guest professor of neurochemistry at University College London and a Wallenberg Academy Fellow.